Bicara Therapeutics Inc. Proceeds from Issuance of Redeemable Convertible Preferred Stock
Bicara Therapeutics Inc. (BCAX) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $272.30 million for the 12-month period ending 2023-12-31, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2025-11-10
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|
| 2023-12-31 | $272.30M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |